1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours.
Saved in:
| Title: | 1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. |
|---|---|
| Authors: | Powderly, J.1 (AUTHOR), Bendell, J.C.2 (AUTHOR), Carneiro, B.A.3 (AUTHOR), Italiano, A.4 (AUTHOR), Mercadé, T. Macarulla5 (AUTHOR), Alvarez, E. Castanon6 (AUTHOR), Imbimbo, M.7 (AUTHOR), Massard, C.8 (AUTHOR), Mueller, N.9 (AUTHOR), Gascó -Hernandez, A.9 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS728-S729. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
